Vinge advises Biotage AB (publ) (“Biotage”) in connection with its acquisition of Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma Biosciences (“Gamma”), a life sciences tools platform created and controlled by KKR.
The acquisition extends Biotage’s chromatography franchise into the higher-growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutic customers.
The purchase price will be paid in new ordinary shares in Biotage, entailing that the KKR-controlled Gamma is expected to become the largest shareholder in Biotage, with an ownership of approximately 17 percent.
The transaction is subject to shareholder approval by the general meeting of Biotage and customary closing conditions, including approvals from the UK authorities.
Vinge’s team consisted of Matthias Pannier, Karl Klackenberg, Linus Adolfsson, Sebastian Saadieh, Elis Allmark (M&A), Dain Hård Nevonen, William Kåge, Joel Magnusson, Anna Svensson, Gabriel Chabo (Capital Markets), Sebastian Örndahl (Anti-trust), Sara Dahlros Sköld and Julia Hagelberg (VDR).
